Validation of XXXX ( @entity2023 and its Impact on Asthma) classification in a pediatric population: the PEDRIAL study.

@entity1984 @entity1 @entity2023 @entity2490 @entity6048
@entity2023 ( @entity1984 ) is the commonest chronic disease in @entity1 . @entity2023 and its Impact on Asthma ( @entity6048 ) classification based on symptom duration (intermittent vs. persistent) and severity (mild vs. moderate/severe) has not been yet validated in @entity1 . Thus our objective was to validate @entity6048 classification in @entity1 , after determining the severity and duration of @entity1984 in a pediatric population, using @entity6048 definitions. @entity1 aged 6-12 with a diagnosis of @entity1984 were included in an observational, cross-sectional, multicenter study. @entity1 were classified according to @entity6048 guidelines. AR symptoms were assessed using the Total Four Symptoms Score (T4SS). Severity was also evaluated by the @entity1 using a visual analogue scale (VAS). Comparisons were made by means of a statistical analysis. One thousand two hundred and seventy-five @entity1 from 271 centers were included. Among them, 59.5% had intermittent and 40.5% persistent @entity1984 , while 60.7% seasonal and 39.3% perennial according to dated classification, with significant differences existing between one classification and another; 89.7% had moderate/severe @entity2490 . Significantly higher T4SS and VAS scores were obtained in moderate/severe compared to mild @entity1984 . In our experience, the current @entity6048 classification can be considered a valid tool also in @entity1 from 6- to 12-yr old.
